Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma

Inhibition of monocarboxylate transporter 1 has been proposed as a therapeutic approach to perturb lactate shuttling in tumor cells that lack monocarboxylate transporter 4. We examined the monocarboxylate transporter 1 inhibitor AZD3965, currently in phase I clinical studies, as a potential therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Noble, Richard A., Bell, Natalie, Blair, Helen, Sikka, Arti, Thomas, Huw, Phillips, Nicole, Nakjang, Sirintra, Miwa, Satomi, Crossland, Rachel, Rand, Vikki, Televantou, Despina, Long, Anna, Keun, Hector C., Bacon, Chris M., Bomken, Simon, Critchlow, Susan E., Wedge, Stephen R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566036/
https://www.ncbi.nlm.nih.gov/pubmed/28385782
http://dx.doi.org/10.3324/haematol.2016.163030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566036/
https://www.ncbi.nlm.nih.gov/pubmed/28385782
http://dx.doi.org/10.3324/haematol.2016.163030

Ejemplares similares